Sachin Pai, MBBS, M.D.
Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical OncologySpecialty: Cancer CareConditions Treated
- Bloating
- Blood Disorder
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Colorectal Cancer
- Endometrial Cancer
- Hemophilia
- Liver Metastases
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Secondary Liver Cancer
- Skin Cancer
- Stomach Cancer
- Uterine Cancer
Board Certifications
- American Board of Internal Medicine (Medical Oncology and Internal Medicine)
Education
- Medical School: Kasturba Medical College | Karnataka, India
- Residency: Manipal University | Karnakata, India
- Fellowship: Ochsner Clinic Foundation | New Orleans, LA
Languages
- English
Clinical Trials
A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer
Treatment for Lung Cancer
A Prospective Quality of Life Study in Metastatic Pancreatic Cancer
Treatment for Pancreatic Cancer
A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizuman in Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Treatment for Melanoma
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors
Treatment for Lung Cancer
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Treatment for Head / Neck Cancer
Phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody
Treatment for Melanoma
Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Treatment for Pancreatic Cancer
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma
Treatment for Hodgkin´s Lymphoma
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer.
Treatment for Pancreatic Cancer
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Treatment for Rare Tumors
University of Chicago UC IRB17-0686 Phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody
Treatment for Melanoma
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Treatment for Lung Cancer